May 13, 2016 — Blue Earth Diagnostics, a molecular imaging diagnostics company, announced it has established operations in the United States in Burlington, Mass. The company develops and commercializes innovative positron emission tomography (PET) imaging products that address unmet needs in cancer.
The Massachusetts headquarters will provide sales, marketing and medical affairs support for the development and commercialization of fluciclovine F-18, the company’s PET imaging agent currently under Priority Review with the U.S. Food and Drug Administration (FDA).
The company also announced the creation of key appointments for Blue Earth Diagnostics Inc.: Michael W. Heslop, as president; Peter Gardiner, MB ChB, MRCP, FFPM, as vice president, medical affairs; Bradley K. Pounds as vice president, sales, U.S.; David Pendleton, vice president, marketing; Christa Dhimo, vice president, strategy & execution, U.S.; and Priscilla Harlan, vice president, corporate communications.
Blue Earth Diagnostics Inc. is a wholly-owned subsidiary of U.K.-based Blue Earth Diagnostics Ltd.
For more information: www.blueearthdiagnostics.com
July 30, 2024 
